Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03226418 2026-03-10

Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia

75 enrolled 14 charts

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT03264404 2026-01-27

Azacitidine and Pembrolizumab in Pancreatic Cancer

36 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04150029 2026-01-13

STIMULUS-AML1

Phase 2 Terminated

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT04266301 2026-01-13

STIMULUS-MDS2

Phase 3 Terminated

530 enrolled 29 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01869114 2025-12-10

Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

57 enrolled 13 charts

Chromosome 5q Deletion Syndrome, Congenital Abnormalities, Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 2 FDA

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 1 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT03268954 2025-10-29

PANTHER

454 enrolled 41 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT02959437 2025-10-21

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

70 enrolled 14 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT04623216 2025-10-16

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

24 enrolled 16 charts

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05168202 2025-09-25

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase 1 Terminated

56 enrolled 24 charts

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

183 enrolled 30 charts

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT04023526 2025-08-20

CULMINATE

103 enrolled 19 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT04102020 2025-08-20

VIALE-M

112 enrolled 13 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 2 FDA

Leukemia, Myeloid, Acute

NCT02546986 2025-08-08

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

100 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02269280 2025-08-07

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

185 enrolled 12 charts

Leukemia, Myelodysplastic Syndromes

NCT05209152 2025-07-14

AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia

Phase 1 Terminated

7 enrolled 16 charts

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01757535 2025-07-08

QUAZAR AML-001

472 enrolled 24 charts 2 FDA

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

LymphoidMyeloidOther hematologic neoplasm

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT02397720 2025-06-08

Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia

150 enrolled 17 charts

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT00629343 2025-06-05

Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide

Other solid neoplasmSarcomaThoracic

27 enrolled 7 charts

Mesothelioma, Sarcoma

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia